USA/AU/EU warehouse supply raw powder Olmesartan CAS144689-24-7 and good price Olmesartan
1 Inquiries
144689-24-7
Pharmaceutical Grade
99%
shenzhen
1kg/bag;25kg/Cardboard Drum
2029-01-31
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOlmesartan is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
Solid
Olmesartan is a biphenylyltetrazole. It has a role as an antihypertensive agent and an angiotensin receptor antagonist.|Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. By comparison, the angiotensin-converting enzyme inhibitor (ACEi) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibit the conversion of angiotensin I to angiotensin II through inhibition of the ACE enzyme. However, this does not prevent the formation of all angiotensin II within the body. The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. Olmesartan is commonly used for the management of hypertension and Type 2 Diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors. ARBs such as olmesartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization. Like other ARBs, olmesartan blockade of RAAS slows the progression of diabetic nephropathy due to its renoprotective effects. Orally available olmesartan is produced as the prodrug olmesartan medoxomil which is rapidly converted in vivo to the pharmacologically active olmesartan. It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.|Olmesartan is an Angiotensin 2 Receptor Blocker. The mechanism of action of olmesartan is as an Angiotensin 2 Receptor Antagonist.|Olmesartan is an angiotensin II receptor blocker used in the therapy of hypertension. Olmesartan is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury.|Olmesartan is a synthetic imidazole derivative and angiotensin II receptor antagonist with antihypertensive activity. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor subtype in vascular smooth muscle and adrenal gland, thereby competing with angiotensin II for binding to the AT1 receptor. This prevents angiotensin II-induced vasoconstriction and interferes with angiotensin II-mediated aldosterone secretion, thereby decreasing aldosterone production and preventing aldosterone-stimulated sodium retention and potassium excretion.Basic Info-
Product Name:
Olmesartan
Other Name:1H-Imidazole-5-carboxylic acid,4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-;1H-Imidazole-5-carboxylic acid,4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-;4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid;RNH 6270;Olmesartan;CS 088;Olmetor
CAS No.:144689-24-7
Molecular Formula:C24H26N6O3
InChIKeys:InChIKey=VTRAEEWXHOVJFV-UHFFFAOYSA-N
Molecular Weight:446.5
Exact Mass:446.50
EC Number:646-413-5
UNII:8W1IQP3U10
NSC Number:759810
DSSTox ID:DTXSID2040571
NCI Thesaurus Code:C66253
HScode:2921590090
Categories:
Characteristics-
PSA:
130
XLogP3:3.2
Appearance:Solid
Density:1.3±0.1 g/cm3
Melting Point:186-188ºC
Boiling Point:738.3°C at 760 mmHg
Flash Point:400.3±35.7 °C
Refractive Index:1.671
Water Solubility:1.05e-02 g/L
Storage Conditions:Store at 20-25 deg C (68-77 deg F)
Vapor Pressure:1.7X10-21 mm Hg at 25 deg C (est)
PKA:4.3None
Henrys Law Constant:Henry's Law constant = 9.25X10-21 atm-cu m/mol at 25 °C (est)
Dissociation Constants:4.3|pKa1 = 0.91 (carboxyl); pKa2 = 4.96 (amine); pKa3 = 5.57 (amine); pKa4 = 13.93 (tertiary alcohol) (est)
Experimental Properties:White to light yellowish-powder or crystalline powder. It is practically insoluble in water and sparingly soluble in methanol /Olmesartan medoxomil/|Hydroxyl radical reaction rate constant = 5.21X10-11 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) none
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Location:
XINYUAN DADUHUI PHASE 1, NO.258 TAOYUAN NORTH ROAD, LIANHU DISTRICT, XI 'AN , SHAANXI CHINA
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
30
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
Germany
Olmesartan
5 G Jul 31, 2026 Post an enquiry for this product
